Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) obtained marketing authorization for its Cetuximab N01 injection from China's National Medical Products Administration, a Friday bourse filing said.
The drug is used in combination with FOLFOX or FOLFIRI regimens for first-line treatment of rat sarcoma virus wild-type metastatic colorectal cancer, according to the biopharmaceutical company.